life scienc tool diagnost decreas target price
pre-announce ebitda million vs million cvet
preliminari result nice ahead expect includ net sale
billion report org even adjust bp benefit
custom stock activ across distribut busi europ apac ahead
org estim geograph basi north america expand organ
vs estimate includ normal growth suppli chain sale
rx manag in-lin recent commentari catch meanwhil
europ increas vs estimate apac emerg market grew vs
estimate profit perspect expect ebitda rang
million vs million estimate million includ million benefit
ou stock impli meaning better profit ebitda margin rel
estim midpoint like demonstr progress intern initi
expect estim withdrew previous issu financi guidanc
ebitda million cite uncertainti relat disrupt
pressur veterinari offic visit go forward also expect neg impact
software-rel sale revenu custom defer certain purchas
decis well core suppli chain sale companion anim revenu
impact vet well visit declin potenti said note
well visit account roughli vet revenu vet optimist
rel rapid rebound traffic follow heighten demand across on-line
prescript manag busi revenue also partial off-set deterior
across core distribut busi also note dist center pharmaci
fulli oper notabl suppli chain constraint except ppe sale
adjust estim reiter neutral encourag better-than-
anticip revenu profit experi lower ep estim
primarili lower suppli chain revenu light deterior vet
traffic volum consist survey work see vet survey
target price move lower view expect detail
cvet earn call may risk shift industri demand transit cost
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
one largest anim health distributor global provid
comprehens servic technolog platform dedic support
companion anim equin larg anim veterinari market
blue sky scenario predic better expect
expans companion anim market support
innov product servic well greater expect
grey sky scenario assum vendor concentr
veterinari practic consolid compress margin also lower
expect revenu synergi captur veterinarian resist wider spread
accept vet first choic platform servic
 close
stock dynam note previous attribut approxim
organ revenu growth million million ebitda stock dynam
associ stock benefit center europ apac
importantli note meaning stock benefit north american sale
assum continu stock benefit
vet first choic detail vet first choic bright spot quarter ralli
roughli million revenu note e-rx platform like strong
contributor profit heighten demand come exist
custom light social distanc protocol vet well increas level new
custom enrol give enrol updat call gener
major revenu cohort join platform earlier suggest
build traction/custom engag encourag indic potenti heighten
telemedicin may provid benefit demand vet prescrib
medic remot accord revis fda state regul
integr telemedicin capabl across pim workflow help veterinarian retain
addit note began sell zoeti outperform tripl combin
flea/tick/heartworm parasiticid simparica trio vet first choic monday april
remain optimist product launch across vet on-line channel despit
current covid environ
impact vet traffic veterinari well visit estim make around
veterinari traffic vet revenu global estim
acknowledg associ volum declin meaning impact suppli
chain revenu said note major vet practic experienc
slowdown oppos full shut-down mani practic begin rebook postpon
appoint may june optimist outlook remaind year
consist commentari recent vet survey
address leverag concern drew million revolv
million manag cash posit expect complianc
bank-defin leverag threshold includ adjust project
synergi cost save march
way background typic experi cash outflow begin year
january/februari associ time year-end payabl season work
capit requir manufactur take inventori recov
remaind quarter addit use million approxim
million net proce divestitur scil anim care pre-pay quarterli term
loan amort payment end million cash hand per
convers compani feel comfort compliant debt
coven particularli consid higher-than-anticip ebitda quarter
remaind note typic stronger cash flow
gener quarter implement cost-cut measur includ salari
reduct execut board senior-level employe furlough hire freez
discretionari spend deferr product relationship lend
institut factor make comfort financi liquid posit
albeit acknowledg uncertainti regard scope durat said
clearli continu monitor leverag dynam go forward
compani mention price
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
